NBSE — NeuBase Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Neubase Therapeutics To Explore Strategic Alternatives
SEC Filing
NeuBase Therapeutics falls on 1-for-20 reverse stock split
Brief: NeuBase Announces 1-For-20 Reverse Stock Split
Brief: Neubase Announces Positive Preclinical Data Supporting The Capabilities Of Stealth Editors
Brief: Neubase Announces Formation Of Gene Editing Advisory Board
NeuBase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Neubase Reports Business Update And Financial Results For The First Quarter Of 2023
NeuBase Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Neubase Therapeutics Board Approved A Change In Co's Fiscal Year
Brief: Neubase Therapeutics Says Nasdaq Notified Co It Was Eligible For Additional 180 Calendar Day Period To Regain Compliance With Minimum Bid Price Requirement
NeuBase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Neubase Therapeutics Reports Business Update And Financial Results For Q1 2023
NeuBase Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Neubase Therapeutics Inc - On Dec 28, 2022, Co Entered Into A Purchase Agreement With Alumni Capital
NeuBase Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Neubase Therapeutics Reports Business Update And Financial Results For Fiscal Year 2022
Brief: Neubase Therapeutics Announces Gene Editing Research Agreement With Global Healthcare Company
Chardan Capital downgrades Neubase to 'neutral' from 'buy'